)
Hyderabad-based Aurobindo Pharma has received the US Food and Drug Administration’s (USFDA) nod to manufacture and market valsartan and hydrochlorothiazide tablets.
“The product is ready for launch,” the company said today.
The drug maker has received the regulator’s approvals for the drug in five different strengths in tablet form.
The drug, that falls under the cardiovascular therapeutic category and used in treatment of hypertension to lower blood pressure, is a generic version of Novartis Pharmaceuticals Corp’s Diovan HCT tablets.
According to industry estimates, the market size of the product is around $1.7 billion for the twelve months ending September 2012.
